Arrivent Biopharma Inc Stock Ownership - Who owns Arrivent Biopharma?

Insider buying vs selling

Have Arrivent Biopharma Inc insiders been buying or selling?
Carl L. GordonDirector2024-01-30222,222$18.00
Carl L. GordonDirector2024-01-30222,222$18.00
James HealyDirector2024-01-30444,444$18.00
Hillhouse Investment Management Ltd10% Owner2024-01-30555,555$18.00
Orbimed Advisors LLCDirector2024-01-30222,222$18.00
Orbimed Advisors LLCDirector2024-01-30222,222$18.00

1 of 1

AVBP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AVBP insiders and whales buy or sell their stock.

AVBP Shareholders

What type of owners hold Arrivent Biopharma Inc stock?
Hillhouse Investment Management Ltd13.39%4,484,672$82.47MInsider
Hhlr Advisors Ltd11.73%3,929,117$72.26MInstitution
Orbimed Advisors LLC9.04%3,027,328$55.67MInstitution
Fmr LLC5.82%1,950,034$35.86MInstitution
Octagon Capital Advisors LP5.80%1,943,836$35.75MInstitution
Sofinnova Investments Inc5.07%1,696,752$31.20MInstitution
James Healy5.07%1,696,752$31.20MInsider
Suvretta Capital Management LLC4.67%1,563,709$28.76MInstitution
Orbimed Advisors LLC4.52%1,513,664$27.84MInsider
Carl L. Gordon4.52%1,513,664$27.84MInsider

1 of 3

AVBP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AVBP65.24%31.26%Net Buying
URGN73.07%26.93%Net BuyingNet Selling
ARCT88.04%11.96%Net SellingNet Selling
RGNX77.88%22.12%Net SellingNet Buying

Arrivent Biopharma Stock Ownership FAQ

Who owns Arrivent Biopharma?

Arrivent Biopharma (NASDAQ: AVBP) is owned by 65.24% institutional shareholders, 31.26% Arrivent Biopharma insiders, and 3.50% retail investors. Hillhouse Investment Management Ltd is the largest individual Arrivent Biopharma shareholder, owning 4.48M shares representing 13.39% of the company. Hillhouse Investment Management Ltd's Arrivent Biopharma shares are currently valued at $82.47M.

If you're new to stock investing, here's how to buy Arrivent Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.